Finance News World

“Chronic Hand Eczema Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hand Eczema Market.

The Chronic Hand Eczema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Hand Eczema Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Hand Eczema treatment therapies with a considerable amount of success over the years.

• Chronic Hand Eczema companies working in the treatment market are Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm Research, Novartis, Basilea Pharmaceutica, and others, are developing therapies for the Chronic Hand Eczema treatment

• Emerging Chronic Hand Eczema therapies in the different phases of clinical trials are- Ruxolitinib cream, Delgocitinib, ASN002, ARQ-252, Acitretin, Pimecrolimus Cream, alitretinoin, and others are expected to have a significant impact on the Chronic Hand Eczema market in the coming years.

• In October 2026, LEO Pharma presented additional clinical and real-world evidence for delgocitinib cream at the 35th European Academy of Dermatology and Venereology (EADV) Congress. Interim results from the German REACHED real-world study showed that 28.6% of adult patients achieved clear or almost clear skin after eight weeks of treatment, compared with none at baseline.

• In September 2026, LEO Pharma announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an extension of ANZUPGO’s indication to adolescents aged 12–17 years with moderate-to-severe CHE.

• In March 2026, LEO Pharma Inc., a global leader in medical dermatology, has announced the launch of its new direct-to-consumer (DTC) multichannel campaign, “It’s GO time,” for ANZUPGO® (delgocitinib) cream the first and only FDA-approved treatment for moderate to severe chronic hand eczema (CHE). The initiative is designed to raise awareness about CHE, strengthen brand visibility, and encourage eligible patients to consult their healthcare providers about ANZUPGO.

• In August 2025, Delgocitinib is a Janus kinase (JAK) inhibitor that works by inhibiting the JAK-STAT signaling pathway, which is known to play a significant role in the development of chronic inflammatory skin disorders. Its approval was based on results from two randomized, double-blind Phase 3 clinical trials—DELTA 1 (NCT04871711) and DELTA 2 (NCT04872101). These studies included adults with moderate-to-severe chronic hand eczema (CHE) who had either responded inadequately to topical corticosteroids or were not suitable candidates for such treatments.

• In July 2025, The US FDA has announced the approval of delgocitinib cream (Anzupgo; LEO Pharma Inc.) for the treatment of adults with moderate-to-severe chronic hand eczema (CHE) who have shown inadequate response to previous topical corticosteroids or for whom such treatments are not recommended. This approval positions delgocitinib as the first and only FDA-approved therapy specifically indicated for this patient population.

• In March 2025, Delgocitinib cream is currently being investigated in the U.S. and other regions. Approved in the European Union, United Kingdom, Switzerland, and the UAE under the brand name Anzupgo®, it is used to treat moderate to severe chronic hand eczema (CHE) in adults when topical corticosteroids are ineffective or unsuitable. Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that targets the JAK-STAT signaling pathway, crucial in the development of CHE. The condition involves skin barrier dysfunction, skin inflammation, and changes to the skin microbiome.

• In February 2025, LEO Pharma A/S, a global leader in medical dermatology, announced positive top-line results for the primary endpoint from the double-blind phase of its Phase 3 DELTA China trial. The study evaluated Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of moderate to severe Chronic Hand Eczema (CHE) in Chinese adolescents and adults (12 years and older) who do not respond adequately to or are unsuitable for topical corticosteroids.

Chronic Hand Eczema Overview

Chronic hand eczema, also known as hand dermatitis, is a long-lasting inflammatory skin condition that causes red, itchy, and inflamed skin on the hands. It is often triggered by exposure to irritants such as soaps, chemicals, or allergens, and can also be exacerbated by frequent hand washing or stress. Symptoms include dryness, cracking, swelling, and sometimes blisters. Chronic hand eczema can significantly impact daily activities due to discomfort and skin damage. Treatment typically includes moisturizing, avoiding triggers, and using topical steroids or other medications to reduce inflammation and manage symptoms.

Get a Free Sample PDF Report to know more about Chronic Hand Eczema Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-hand-eczema-pipeline-insight

Emerging Chronic Hand Eczema Drugs Under Different Phases of Clinical Development Include:

• Ruxolitinib cream: Incyte Corp

• Delgocitinib: LEO Pharma

• ASN002: Asana BioSciences

• ARQ-252: Arcutis Biotherapeutics

• Acitretin: Innovaderm Research

• Pimecrolimus Cream: Novartis

• alitretinoin: Basilea Pharmaceutica

Chronic Hand Eczema Route of Administration

Chronic Hand Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Chronic Hand Eczema Molecule Type

Chronic Hand Eczema Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Chronic Hand Eczema Pipeline Therapeutics Assessment

• Chronic Hand Eczema Assessment by Product Type

• Chronic Hand Eczema By Stage and Product Type

• Chronic Hand Eczema Assessment by Route of Administration

• Chronic Hand Eczema By Stage and Route of Administration

• Chronic Hand Eczema Assessment by Molecule Type

• Chronic Hand Eczema by Stage and Molecule Type

DelveInsight’s Chronic Hand Eczema Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Hand Eczema product details are provided in the report. Download the Chronic Hand Eczema pipeline report to learn more about the emerging Chronic Hand Eczema therapies

Some of the key companies in the Chronic Hand Eczema Therapeutics Market include:

Key companies developing therapies for Chronic Hand Eczema are – GlaxoSmithKline, Pfizer, Sanofi, Johnson & Johnson, Novartis, and others.

Chronic Hand Eczema Pipeline Analysis:

The Chronic Hand Eczema pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hand Eczema with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hand Eczema Treatment.

• Chronic Hand Eczema key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Hand Eczema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hand Eczema market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Hand Eczema drugs and therapies

Chronic Hand Eczema Pipeline Market Drivers

• Rising Prevalence of Chronic Hand Eczema: Increasing cases of chronic hand eczema, particularly among healthcare workers, hairdressers, food handlers, and other occupational groups exposed to irritants and allergens, are driving demand for effective treatments.

• High Unmet Medical Need: Limitations of conventional treatments, particularly topical corticosteroids for long-term disease management, are creating demand for safer and more effective therapeutic alternatives.

• Advancements in Targeted Therapies: Development of novel treatments, including topical JAK inhibitors, biologics, and other immunomodulatory therapies, is expanding the treatment landscape.

• Growing Disease Awareness and Diagnosis: Increasing awareness among healthcare professionals and patients, along with improved diagnostic approaches, is supporting early identification and treatment.

• Increasing Focus on Quality of Life: The significant impact of chronic hand eczema on daily activities, occupational productivity, and psychological well-being is encouraging greater adoption of effective disease management strategies.

Chronic Hand Eczema Pipeline Market Barriers

• Diagnostic Challenges: The heterogeneous clinical presentation and overlapping symptoms with conditions such as atopic dermatitis and contact dermatitis can lead to misdiagnosis and delayed treatment.

• Limitations of Existing Treatments: Topical corticosteroids may cause adverse effects with prolonged use, while some patients experience inadequate responses or disease recurrence.

• High Treatment Costs: Novel targeted therapies and long-term treatment requirements may increase healthcare expenses and restrict access for certain patient populations.

• Treatment Non-adherence: Prolonged disease duration, recurring symptoms, treatment complexity, and concerns about medication-related adverse effects can reduce patient adherence.

• Limited Clinical Evidence: Variability in disease subtypes and the lack of extensive comparative clinical data for emerging therapies may create challenges in establishing standardized treatment approaches.

Scope of Chronic Hand Eczema Pipeline Drug Insight

• Coverage: Global

• Key Chronic Hand Eczema Companies: Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm Research, Novartis, Basilea Pharmaceutica, and others

• Key Chronic Hand Eczema Therapies: Ruxolitinib cream, Delgocitinib, ASN002, ARQ-252, Acitretin, Pimecrolimus Cream, alitretinoin, and others

• Chronic Hand Eczema Therapeutic Assessment: Chronic Hand Eczema current marketed and Chronic Hand Eczema emerging therapies

• Chronic Hand Eczema Market Dynamics: Chronic Hand Eczema market drivers and Chronic Hand Eczema market barriers

Request for Sample PDF Report for Chronic Hand Eczema Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Hand Eczema Report Introduction

2. Chronic Hand Eczema Executive Summary

3. Chronic Hand Eczema Overview

4. Chronic Hand Eczema- Analytical Perspective In-depth Commercial Assessment

5. Chronic Hand Eczema Pipeline Therapeutics

6. Chronic Hand Eczema Late Stage Products (Phase II/III)

7. Chronic Hand Eczema Mid Stage Products (Phase II)

8. Chronic Hand Eczema Early Stage Products (Phase I)

9. Chronic Hand Eczema Preclinical Stage Products

10. Chronic Hand Eczema Therapeutics Assessment

11. Chronic Hand Eczema Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Hand Eczema Key Companies

14. Chronic Hand Eczema Key Products

15. Chronic Hand Eczema Unmet Needs

16 . Chronic Hand Eczema Market Drivers and Barriers

17. Chronic Hand Eczema Future Perspectives and Conclusion

18. Chronic Hand Eczema Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services